# A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols

> **NCT00884312** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 101 (actual)

## Conditions studied

- Multiple Myeloma
- Solid Tumors

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT00884312
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04-09
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-05-17
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2018-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00884312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00884312, "A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00884312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*